Organon & Company Aktie 111523364 / US68622V1061
15.28
USD
0.40
USD
2.65%
22.11.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Organon Company Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Organon & Company | 7.77 | 1.12 | USD |
| 2022 | Organon & Company | 4.01 | 1.12 | USD |
| 2021 | Organon & Company | 1.84 | 0.56 | USD |
| 2020 | Organon & Company | - | - | USD |
| 2019 | Organon & Company | - | - | USD |
| 2018 | Organon & Company | - | - | USD |
| 2017 | Organon & Company | - | - | USD |
Gewinn je Aktie- Organon & Company
| 7.1 17 | 8.5 18 | 12.7 19 | 8.5 20 | 5.3 21 | 3.6 22 | 4.0 23 |
Umsatz je Aktie- Organon & Company
| 41.5 17 | 38.6 18 | 37.6 19 | 32.0 20 | 25.1 21 | 24.2 22 | 24.4 23 |
KGV- Organon & Company
| 5.7 21 | 7.8 22 | 3.6 23 |
Organon & Company: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 7.11 | 8.51 | 12.71 | 8.53 | 5.31 | 3.59 | 3.99 |
| Gewinn je Aktie unverwässert | 7.11 | 8.51 | 12.71 | 8.53 | 5.33 | 3.61 | 4.01 |
| Gewinn je Aktie verwässert | 7.11 | 8.51 | 12.71 | 8.53 | 5.33 | 3.59 | 3.99 |
| Dividende pro Aktie | - | - | - | - | 0.56 | 1.12 | 1.12 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 145.00 | 290.00 | 294.00 |
Organon & Company: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 41.48 | 38.62 | 37.65 | 31.98 | 25.08 | 24.20 | 24.44 |
| KGV (Jahresendkurs, EPS unverwässert) | - | - | - | - | 5.71 | 7.77 | 3.61 |
| KGV (Jahresendkurs, EPS verwässert) | - | - | - | - | 5.71 | 7.77 | 3.61 |
| KGV (Jahresendkurs) | - | - | - | - | 5.71 | 7.77 | 3.61 |
| Dividendenrendite Jahresende in % | - | - | - | - | 1.84 | 4.01 | 7.77 |
| Eigenkapitalquote in % | - | 60.49 | 66.70 | 55.30 | -14.12 | -8.14 | -0.58 |
| Fremdkapitalquote in % | - | 39.51 | 33.30 | 44.70 | 114.12 | 108.14 | 100.58 |
Organon & Company: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 10’500.00 | 9’777.00 | 9’530.00 | 8’096.00 | 6’360.00 | 6’174.00 | 6’263.00 |
| Umsatzveränderung in % | - | -6.89 | -2.53 | -15.05 | -21.44 | -2.92 | 1.44 |
| Bruttoergebnis vom Umsatz | 5’912.00 | 5’091.00 | 5’916.00 | 4’752.00 | 3’978.00 | 3’894.00 | 3’748.00 |
| Bruttoergebnisveränderung in % | - | -13.89 | 16.21 | -19.68 | -16.29 | -2.11 | -3.75 |
| Operatives Ergebnis | 3’272.00 | 2’713.00 | 3’662.00 | 2’782.00 | 1’872.00 | 1’719.00 | 1’327.00 |
| Veränderung Operatives Ergebnis in % | - | -17.08 | 34.98 | -24.03 | -32.71 | -8.17 | -22.80 |
| Ergebnis vor Steuern | 3’099.00 | 2’729.00 | 3’555.00 | 2’680.00 | 1’529.00 | 1’122.00 | 673.00 |
| Veränderung Ergebnis vor Steuern in % | - | -11.94 | 30.27 | -24.61 | -42.95 | -26.62 | -40.02 |
| Ergebnis nach Steuer | 1’801.00 | 2’153.00 | 3’218.00 | 2’160.00 | 1’351.00 | 917.00 | 1’023.00 |
| Veränderung Ergebnis nach Steuer in % | - | 19.54 | 49.47 | -32.88 | -37.45 | -32.12 | 11.56 |
Organon & Company: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | - | 4’146 | 3’513 | 4’434 | 12’189 | 11’847 | 12’128 |
| Langzeit Gesamtverbindlichk. pro Aktie | - | 10.28 | 8.58 | 7.70 | 37.83 | 36.70 | 36.03 |
| Eigenkapital | - | 6’348 | 7’035 | 5’486 | -1’508 | -892 | -70 |
| Veränderung Eigenkapital in % | - | - | 10.82 | -22.02 | -127.49 | 40.85 | 92.15 |
| Bilanzsumme | - | 10’494 | 10’548 | 9’920 | 10’681 | 10’955 | 12’058 |
| Veränderung Bilanzsumme in % | - | - | 0.51 | -5.95 | 7.67 | 2.57 | 10.07 |
Organon & Company: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 7.11 | 8.51 | 12.71 | 8.53 | 5.33 | 3.61 | 4.01 |
| Veränderung Gewinn je Aktie (unverwässert) in % | - | 19.54 | 49.47 | -32.88 | -37.56 | -32.27 | 11.05 |
| Gewinn je Aktie (verwässert) | 7.11 | 8.51 | 12.71 | 8.53 | 5.33 | 3.59 | 3.99 |
| Veränderung Gewinn je Aktie (verwässert) in % | - | 19.54 | 49.47 | -32.88 | -37.56 | -32.55 | 11.08 |
| Anzahl Mitarbeiter | - | - | 10’445 | 9’950 | 9’300 | 10’000 | 10’000 |
| Veränderung Anzahl Mitarbeiter in % | - | - | - | -4.74 | -6.53 | 7.53 | 0.00 |
Organon & Company Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Organon & Company | Quartalszahlen | 13.02.2025 |
| Organon & Company | Quartalszahlen | 01.05.2025 |
| Organon & Company | Quartalszahlen | 12.08.2025 |
| Organon & Company | Quartalszahlen | 30.10.2025 |
Organon & Company vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 31.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 06.08.2024 |
| Hauptversammlung | Annual General Meeting | 04.06.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 02.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 15.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 02.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 08.08.2023 |
| Hauptversammlung | Annual General Meeting | 06.06.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 04.05.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 16.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 03.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 07.06.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 05.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 17.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.78 |
| The Vanguard Group, Inc. | 11.88 |
| Vanguard Group, Inc. (Subfiler) | 11.56 |
| BlackRock Fund Advisors | 8.84 |
| iShares Core S&P Small Cap ETF | 6.36 |
| Mawer Investment Management Ltd. | 4.99 |
| Massachusetts Financial Services Co. | 3.79 |
| SSgA Funds Management, Inc. | 3.69 |
| State Street Corp. | 3.49 |
| Vanguard Total Stock Market ETF | 3.14 |
| LSV Asset Management | 2.91 |
| Nordea Investment Management AB (Denmark) | 2.62 |
| BlackRock Institutional Trust Co. NA | 2.55 |
| Vanguard Small Cap Index Fund | 2.51 |
| Janus Henderson Contrarian Fund | 2.16 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 10’445 | 9’950 | 9’300 | 10’000 | 10’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.91 | 0.81 | 0.68 | 0.62 | 0.63 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 3’955 | 3’378 | 3’760 | 3’931 | 4’508 |
| Summe Anlagevermögen | 6’593 | 6’542 | 6’921 | 7’024 | 7’550 |
| Summe Aktiva | 10’548 | 9’920 | 10’681 | 10’955 | 12’058 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 186 | 1’241 | 9’364 | 9’112 | 8’931 |
| Summe Fremdkapital | 3’513 | 4’434 | 12’189 | 11’847 | 12’128 |
| Summe Eigenkapital | 7’035 | 5’486 | -1’508 | -892 | -70 |
| Summe Passiva | 10’548 | 9’920 | 10’681 | 10’955 | 12’058 |
Adresse
| 30 Hudson Street, 07302 Jersey City | |
| Telefon | +1 (551) 430-6900 |
| URL | http://www.organon.com |
Management
|
Aaron Falcione
Chief Human Resources Officer |
|
Carrie Smith Cox
Chairman |
|
Charlotte Owens
Head-Medical Affairs & Outcomes Research |
|
Cynthia M. Patton
Independent Director |
|
Daniel Karp
Chief Business Development Officer |
|
Deborah R. Leone
Independent Director |
|
Grace Puma Whiteford
Independent Director |
|
Helene D. Gayle
Independent Director |
|
Jennifer Halchak
Head-Investor Relations |
|
Joseph T. Morrissey
Executive VP, Head-Manufacturing & Supply |
|
Juan Camilo Arjona Ferreira
Chief Medical Officer & Head- R&D |
|
Kate C. Liebelt
Chief of Staff & Executive Director |
|
Kathryn DiMarco
Senior Vice President-Finance & Controller |
|
Kevin Ali
Chief Executive Officer & Director |
|
Kirke Weaver
Secretary, Executive VP & General Counsel |
|
Ma. Fatima D. de Vera Francisco
Independent Director |
|
Marcel van Duin
Chief Scientific Officer |
|
Martha E. McGarry
Independent Director |
|
Matthew M. Walsh
Chief Financial Officer & Executive Vice President |
|
Michael Pergine
Chief Government Affairs & Policy Officer |
|
Philip O. Ozuah
Independent Director |
|
R. Alan B. Ezekowitz
Independent Director |
|
Rachel A. Stahler
Chief Information Officer & Executive VP |
|
Rebecca Lowell Edwards
Chief Communications Officer |
|
Robert A. Essner
Independent Director |
|
Rochelle B. Lazarus
Independent Director |
|
Shalini Sharp
Independent Director |
|
Susan O'Neal
Chief Ethics & Compliance Officer |
|
Susanne Gabriele Fiedler
Chief Commercial Officer & Executive VP |
|
Vittorio Nisita
Executive VP & Head-Global Business Services |